Talzenna Receives New Indication, With Enzalutamide, for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Mutation.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 4, p. 14
- Publication type:
- Article
Works matching IS 21534888 AND DT 2023 AND VI 14 AND IP 4
Results: 16
1
2
Vanflyta Now Approved for Newly Diagnosed FLT3-ITD-Positive AML.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 4, p. 14
- Publication type:
- Article
3
Jemperli Plus Chemotherapy Now FDA Approved for Front-Line Treatment of dMMR or MSI-H Endometrial Cancer.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 4, p. 13
- Publication type:
- Article
4
Would You Trust an AI Doctor? New Research Shows Patients Are Split.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 4, p. 13
- Publication type:
- Article
5
Lonsurf Receives New Indication, in Combination With Bevacizumab, for Previously Treated Metastatic Colorectal Cancer.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 4, p. 12
- Publication type:
- Article
6
U.S. Patients Rely On Generic Medicines But Increases In Drug Shortages Reflect Challenges To Their Long-Term Sustainability.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 4, p. 11
- By:
- Publication type:
- Article
7
Liquid Biopsies on the Horizon for Children With Solid Cancers.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 4, p. 10
- By:
- Publication type:
- Article
8
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 4, p. 9
- By:
- Publication type:
- Article
9
Final OS Analysis Confirms Benefit of Pembrolizumab Plus Chemotherapy With or Without Bevacizumab for First-Line Treatment of Cervical Cancer.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 4, p. 8
- By:
- Publication type:
- Article
10
Epkinly FDA Approved for Treatment of Advanced Diffuse Large B-Cell Lymphoma.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 4, p. 7
- Publication type:
- Article
11
Ribociclib Plus Endocrine Therapy Improves Invasive Disease-Free Survival in Patients With HR-Positive, HER2-Negative, Early Breast Cancer.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 4, p. 7
- By:
- Publication type:
- Article
12
FDA Approves Columvi for Select Patients With Relapsed or Refractory Large B-Cell Lymphomas.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 4, p. 5
- Publication type:
- Article
13
Partnering With Patients Key to Improving Healthcare Outcomes.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 4, p. 1
- By:
- Publication type:
- Article
14
Physician Debate: Is Chemotherapy Still the Backbone for CCA Treatment?
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 4, p. 1
- Publication type:
- Article
15
Survey Offers Snapshot of Patient and Provider Perceptions of AI Use in Healthcare.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 4, p. 1
- Publication type:
- Article
16
Improving Diversity in Clinical Trials.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 4, p. 1
- By:
- Publication type:
- Article